We have discovered that a small peptide degrades the β-amyloid protein that causes Alzheimer's disease, and have named such an enzyme peptide "Catalytide". The discovery of Catalytide is scientifically extremely interesting because it overturns the conventional concept of enzymes and raises expectations for the development of therapeutic drugs for Alzheimer's disease and the use of small molecule peptides in various industries. The Catalytide Research Lab was founded with the mission of exploring the unlimited potential of Catalytide.
The number of patients with Alzheimer's disease (AD) and Parkinson's disease (PD) continues to increase in the aging society and has become a major social problem. Therefore, the development of effective therapeutic drugs for these diseases is urgently needed, but despite numerous development studies, no effective therapeutic drugs have yet been developed. We have shown that small peptides not only promote degradation and inhibit aggregation of amyloid-β, but also inhibit and disassemble α-synuclein aggregation, which causes PD. We believe that small peptides have the potential to be fundamental AD/PD drugs that can not only suppress the progression of AD/PD, but also improve the disease after its onset.
Catalytide Research Lab is looking for people who share our dream. Please see our Recruitment for job openings.
Staff at Catalytide Research Lab